BEIJING, May 26, 2011 /PRNewswire/ -- MicroConstants China Inc., a Contract Research Organization (CRO) conducting preclinicalpharmacokinetics studies and providing full-service early stage clinical trial management in Beijing, announces the Endorsement of Compliance with the OECD Principles of Good Laboratory Practice (GLP) in the areas of analytical chemistry and
Dr. Q. David Yang, chief executive officer of MicroConstants China, is thrilled with the OECD Endorsement of GLP Compliance. "The Endorsement illustrates our commitment to quality and validates our bioanalytical laboratory's capability of carrying out method validation and bioanalysis under OECD Principles of GLP."
MicroConstants China received the Endorsement on May 23, 2011 following a one week assessment and onsite inspection conducted by the Netherlands GLP Compliance Monitoring Programme in early 2011. Late last year, they also received ISO-17025 accreditation from the China National Accreditation Service for Conformity Assessment (CNAS). These accomplishments can be attributed to MicroConstants San Diego's quality systems, which MicroConstants China adopted and successfully implemented at the Beijing laboratory in 2009.
"This Endorsement, along with the CNAS accreditation achieved last year, demonstrates that our Beijing team is capable of conducting high quality contract research services equivalent to those provided by our San Diego bioanalytical laboratory," said Dr. Gilbert Lam, co-founder of MicroConstants China and president of MicroConstants, Inc. in San Diego, California. "This is a significant accomplishment and we are very proud of their progress."
About MicroConstants China Inc.
MicroConstants China Inc. is a Contract Research Organization (CRO) that was established in 2007 by the founder and president of MicroConstants, Inc., a bioanalytical and PK specialty CRO in San Diego, California with over a decade of GLP compliance history. Located in Beijing, MicroConstants China provides preclinical and clinical pharmacokinetic analysis and early stage clinical trial management services, including clinical site qualification, trial monitoring, data management, biostatistics, and clinical summary reports to pharmaceutical and biotech companies worldwide. Additionally, the CRO offers QA audit and drug development project management services for preclinical toxicology and pharmacology studies in China. Its bioanalytical laboratory is fully GLP-compliant with USFDA, OECD, Japan MHLW and China SFDA guidelines. For more information about MicroConstants China and the contract research services they provide, please visit http://www.microconstants.com/china.
SOURCE MicroConstants China Inc.
Subscribe to our Free Newsletters!
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...